Leptin and IL-13Ra2 promote airway eosinophilia in obesity-associated asthma

被引:0
作者
不详
机构
[1] Department of Medicine, Duke University Medical Center, Durham, NC
[2] Department of Pediatrics, University of North Carolina, Chapel Hill, NC
[3] Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, NY
[4] Duke Human Vaccine Institute, Duke University, Durham, NC
[5] Department of Internal Medicine, Yale University, New Haven, Conn
[6] Department of Medicine, University of Michigan, Ann Arbor, Mich
[7] Department of Pathology, Duke University Medical Center, Durham, NC
[8] School of Nursing, Duke University, Durham, NC
基金
美国国家卫生研究院;
关键词
airway fibroblast; eosinophils; eotaxin; IL-13Rα2; leptin; obesity; T2; asthma;
D O I
10.1016/j.jaci.2024.10.039
中图分类号
R392 [医学免疫学];
学科分类号
100102 ;
摘要
Background: Airway tissue eosinophilia can be an observed feature of obesity-associated type 2 (T2) asthma, but the processes mediating this inflammation are unknown. Objective: To investigate a process whereby leptin, an adipokine elevated in obesity, potentiates pulmonary eosinophilia and eotaxin production by airway fibroblasts in T2 asthma. Methods: We assessed associations between body mass index and airway eosinophilia as well as leptin and eotaxin production in 82 participants with asthma, 37 of whom exhibited obesity. Cultured human airway fibroblasts and mouse models of chronic allergic airway disease were used to evaluate leptin's effect on eotaxin production and lung eosinophilia. The role of IL-13 receptor alpha 2 (IL-13Rα2) in mediating these processes was examined using specific neutralizing antibodies in vitro. Results: In participants with T2 asthma and obesity, we observed that airway tissue eosinophilia did not associate with traditional T2 inflammation metrics such as peripheral and/or bronchoalveolar lavage fluid eosinophil counts or with fractional exhaled nitric oxide. Alternatively, we observed elevated bronchoalveolar lavage fluid leptin and eotaxin-1 levels. In airway fibroblasts from participants with asthma, leptin augmented IL-13–induced eotaxin-1 and eotaxin-3 production and IL13RA2 expression. In mice, elevated leptin promoted airway IL-13Rα2 and eotaxin production by lung fibroblasts and lung tissue eosinophilia following chronic house dust mite allergen exposure. Inhibition of IL-13Rα2 reduced combined leptin and IL-13–stimulated eotaxin secretion by human airway fibroblasts. Conclusions: We identified a potential association explaining airway tissue eosinophil retention in obesity-associated T2 asthma through leptin-mediated enhancement of IL-13–induced eosinophil chemokine production by airway fibroblasts, a process requiring IL-13Rα2. © 2024 American Academy of Allergy, Asthma & Immunology
引用
收藏
页码:792 / 797
页数:6
相关论文
共 85 条
  • [1] Ward Z.J., Bleich S.N., Cradock A.L., Barrett J.L., Giles C.M., Flax C., Et al., Projected U.S. state-level prevalence of adult obesity and severe obesity, N Engl J Med, 381, pp. 2440-2450, (2019)
  • [2] Most recent asthma data. Atlanta, Ga: Centers for Disease Control and Prevention, (2016)
  • [3] Scott H.A., Ng S.H.M., McLoughlin R.F., Valkenborghs S.R., Nair P., Brown A.C., Et al., Effect of obesity on airway and systemic inflammation in adults with asthma: a systematic review and meta-analysis, Thorax, 78, pp. 957-965, (2023)
  • [4] Sutherland E.R., Goleva E., Strand M., Beuther D.A., Leung D.Y.M., Body mass and glucocorticoid response in asthma, Am J Respir Crit Care Med, 178, pp. 682-687, (2008)
  • [5] Sposato B., Scalese M., Milanese M., Masieri S., Cavaliere C., Latorre M., Et al., Factors reducing omalizumab response in severe asthma, Eur J Intern Med, 52, pp. 78-85, (2018)
  • [6] FitzGerald J.M., Bleecker E.R., Menzies-Gow A., Zangrilli J.G., Hirsch I., Metcalfe P., Et al., Predictors of enhanced response with benralizumab for patients with severe asthma: pooled analysis of the SIROCCO and CALIMA studies, Lancet Respir Med, 6, pp. 51-64, (2018)
  • [7] Ortega H., Li H., Suruki R., Albers F., Gordon D., Yancey S., Cluster analysis and characterization of response to mepolizumab. A step closer to personalized medicine for patients with severe asthma, Ann Am Thorac Soc, 11, pp. 1011-1017, (2014)
  • [8] Moore W.C., Meyers D.A., Wenzel S.E., Teague W.G., Li H., Li X., Et al., Identification of asthma phenotypes using cluster analysis in the Severe Asthma Research Program, Am J Respir Crit Care Med, 181, pp. 315-323, (2010)
  • [9] Haldar P., Pavord I.D., Shaw D.E., Berry M.A., Thomas M., Brightling C.E., Et al., Cluster analysis and clinical asthma phenotypes, Am J Respir Crit Care Med, 178, pp. 218-224, (2008)
  • [10] Lefaudeux D., De Meulder B., Loza M.J., Peffer N., Rowe A., Baribaud F., Et al., U-BIOPRED clinical adult asthma clusters linked to a subset of sputum omics, J Allergy Clin Immunol, 139, pp. 1797-1807, (2017)